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Naturally occurring deletions within the human hepatitis B virus (HBV) preS2 region have frequently been identified in
patients with hepatocellular carcinoma (HCC), while chronic carriers without cirrhosis and HCC contain no detectable preS2
deletion variants. We have characterized two different preS2 internal deletion variants from two patients. In addition to
several weak phenotypes, our study revealed three unexpected strong phenotypes: (1) a paradoxical “hypermodification”
phenomenon was observed with significantly increased size heterogeneity and molecular weights of the secreted middle (M)
envelope proteins containing a preS2 internal deletion. This phenomenon was observed in transient transfection with a
human hepatoma Huh7 cell line as well as in stable transfection with a rodent hepatoma cell line 7777. (2) A significantly
increased intracellular accumulation of all three envelope proteins (large, middle, and small) was detected by both Western
blot analysis and immunofluorescence microscopy. (3) The middle envelope proteins with a preS2 internal deletion were not
recognized in vitro by a putative neutralizing antiserum, suggesting that these variants can evade immune recognition in vivo.
To our knowledge, this is the first identification and characterization of the M deletion variant protein in HBV natural infection.
© 2002 Elsevier Science
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variants.INTRODUCTION
Human hepatitis B virus (HBV) produces three differ-
ent, yet structurally related, envelope proteins from a
single open reading frame (ORF) (Fig. 1). This ORF con-
tains three in-frame translational initiation codons, divid-
ing it into three regions: preS1, preS2, and S (Ganem,
1996; Gerlich et al., 1993). The three envelope proteins,
including large (L) (p39/gp42), middle (M) (gp33/gp36),
and small (S, major surface antigen) (p24/gp27), are
cocarboxy-terminal proteins with different amino-termi-
nal extensions. They share a common N-linked glycosyl-
ation site (Asn-X-Ser/Thr) at amino acid 320 of the S
region, while the M envelope protein has an additional
N-glycosylation site at Asn123 within its preS2 region
(Stibbe and Gerlich, 1983). In addition to N-glycosylation,
O-glycosylation of the preS2 region of M protein has
been reported (Schmitt et al., 1999; Tolle et al., 1998; Werr
and Prange, 1998). The N-glycosylation site at Asn320 is
only partially utilized in three envelope proteins (gp42,
gp36, and gp27), in contrast to the full utilization of
Asn123 in the M envelope protein (gp33 and gp36)
(Schmitt et al., 1999). All these envelope proteins insert
into the rough endoplasmic reticulum (RER) cotransla-
tionally as integral membrane proteins (Eble et al., 1986,
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441990; Simon et al., 1988). HBV virions and subviral parti-
cles are formed at the ER or the pre-Golgi compartment
and are secreted by the constitutive secretory pathway
(Huovila et al., 1992; Patzer et al., 1984, 1986).
The expression of L and S envelope proteins is nec-
essary for virion formation and secretion (Bruss and
Ganem, 1991; Poisson et al., 1997; Ueda et al., 1991). The
L envelope protein has been reported to play a regula-
tory role in the life cycle of hepadnaviruses (Lenhoff and
Summers, 1994). By contrast, the M protein has been
demonstrated to be functionally nonessential for hepad-
navirus assembly or DNA replication (Bruss and Ganem,
1991; Fernholz et al., 1993). Both preS1 and preS2 regions
have been hypothesized to be capable of binding to
putative cellular receptors for viral entry (Gerlich et al.,
1993; Neurath et al., 1986). In addition, the carboxyl-
terminus-truncated M protein has been shown to display
a transcriptional transactivator activity in vitro (Hildt et al.,
1995). To date, the functional role of M protein remains
unclear.
In addition to their functional and structural roles, the
preS1 and preS2 regions carry potent T and B cell
epitopes (Chisari and Ferrari, 1995; Michel et al., 1995;
Milich, 1997; Neurath et al., 1984). Antibodies to preS1
and preS2 regions often appear early in patients who
recover from acute hepatitis B (Coursaget et al., 1988). In
addition, they are often absent in chronic carriers, sug-
gesting a crucial role in viral clearance (Alberti et al.,
45IMMUNE ESCAPE AND HYPERMODIFICATION OF HBV preS2 VARIANT1990; Budkowska et al., 1986, 1992; Ise et al., 1988;
Klinkert et al., 1986; Neurath et al., 1985). Both anti-preS1
and anti-preS2 antibodies have been shown to provide
protection in experimentally challenged chimpanzees
(Emini et al., 1989; Itoh et al., 1986; Neurath et al., 1986a,
1989).
Naturally occurring preS1 and preS2 deletions have
been found in serum samples from HBV carriers (Gerken
et al., 1991; Raimondo et al., 1991; Santantonio et al.,
1992; Tran et al., 1991; Yamamoto et al., 1994; Kidd-
Ljunggren et al., 1995; Pollicino et al., 1995; Preikschat et
al., 1999; Gunther et al., 1999). Despite the fact that most
of these earlier reports used only a small number of
clinical cases, altogether they indicate that a preS dele-
tion is likely to be a frequent event in HBV carriers. For
example, 6 of 6 (100%) Japanese patients were found to
contain preS2 deletions (Yamatomo et al., 1994). On the
other hand, when HBV DNAs from 30 Italian chronic
carriers were systematically examined, no significant
rearrangement in the preS1 region was found and only
one case (3%) contained preS2 deletion mutations (Pol-
licino et al., 1995). Similar studies were done in Thailand
and only 4 of 34 (12%) HBsAg carriers contained the
preS2 deletion (Kidd-Ljunggren et al., 1995). The reason
for discrepancy in the prevalence rates (100% vs 3%)
among these preS mutation results remains unclear.
Most recently, the prevalence rate of preS mutations was
reported to be correlated with different replicative stages
FIG. 1. Cartoon illustration of three related large (L), middle (M), and
small (S) HBV envelope proteins. The top box represents the entire
envelope open reading frame divided into preS1, preS2, and S domains.
Methionines at positions 1, 120, and 175 indicate the respective trans-
lational initiation sites for L, M, and S envelope proteins. Position 400
is the common termination site for all three envelope proteins. The
letter “a” indicates the group a determinant, which is located between
amino acids 298 and 322 and is shared by all three envelope proteins.
The symbol `? ? represents N-linked complex glycans at Asn 123 and
320. Unlike Asn 123, Asn 320 is not always glycosylated. Consequently,
HBV produces both nonglycosylated and glycosylated L and S enve-
lope proteins, in addition to singly and doubly glycosylated M proteins.of chronic HBV infection (Fan et al., 2001).To address the discrepancy of the reported prevalence
rates of preS deletions as well as to extend our hypoth-
esis of HBV immune escape mutations (Hosono et al.,
1995; Tai et al., 1997), we examined the preS sequences
in 20 different serum samples from chronic carriers with-
out cirrhosis and HCC as well as in 12 different liver
samples from 10 different HCC patients. Our study dem-
onstrates that the preS2 internal deletion, which coin-
cides with potent T and B cell epitopes, is a highly
frequent event in Taiwanese hepatocellular carcinoma
patients. The emergence of preS2 variants is probably
caused by immunoevasion from the neutralizing anti-
body. Most interestingly, in our functional characteriza-
tions of two different preS2 deletions found in two differ-
ent patients, we encountered several unexpected and
intriguing phenotypes, including the “hypermodification”
of the secreted M envelope proteins.
RESULTS
PreS2 deletions are found frequently in HCC patients
and rarely in noncirrhotic, non-HCC chronic carriers
Previously, we reported that nonrandom missense mu-
tations of HBsAg and HBcAg accumulated in MHC class
I- and II-restricted T cell epitopes, respectively (Hosono
et al., 1995; Tai et al., 1997). To investigate the generality
of this phenomenon, we extended our work to other
HBV-encoded proteins, the L and M envelope proteins
and their promoter regions for transcription. Our se-
quencing study indicates that mutations occurred rarely
within the preS1 promoter for transcription (data not
shown). Instead of point mutations, highly frequent dele-
tions were found within both preS1 and preS2 regions
(Fig. 2). While we did detect mutations in the S gene (Tai
et al., 1997), we did not find any common S-gene muta-
tions between samples D32 and D79 (data not shown),
which were used for further study in this paper (see
below). PreS2 internal deletion is the only common mu-
tation of the envelope ORF found in both D32 and D79.
Finally, deletions in both preS1 and preS2 regions were
rarely found in the same molecular clone (data not shown).
The preS1 deletions, found in 5 of 10 Taiwanese HCC
patients (T4, T/N117, NCG22, N85, and T/N 109), often
deleted the overlapping promoter element necessary for
transcribing M and S envelope-specific mRNAs (data not
shown). The preS2 deletions, found in 6 of 10 Taiwanese
HCC patients (T4, T/N117, T32, N79, N85, N109), were
concentrated at the amino-terminal half of the preS2
domain (Fig. 2). Although wild-type HBV with no preS2
deletions was not detected in samples T32 and N79, it
existed as a mixture with preS2 deletion variants in
samples T4, N85, and T/N 109 (Fig. 2). In contrast to the
results of HCC patients, we found no preS2 deletions in 20
Taiwanese chronic carriers without clinically apparent cir-
rhosis and HCC (Materials and Methods) (data not shown).
As a side note, except for clone NCG22.4, most of our preS1
pe, but
46 TAI ET AL.and preS2 deletions do not have the splicing consensus
sequences at the deletion junctions (data not shown).
Two major types of preS2 variants: Internal deletion
vs AUG ablation
The preS2 region contains 55 amino acids from codon
120 to 174 (the numbering starts from the N-terminus of
the preS1 region). As shown in Fig. 2, deletions are
frequent in the N-terminal half, while point mutations are
more common near the C-terminal preS2 region. In-
frame deletions were found in 6 of 10 patients: T4,
FIG. 2. The comparison of the deduced amino acid sequence of the
and naturally occurring variants in tumor and nontumor liver tissues.
detected by Southern blot analysis, were used here for PCR subcloning
B associated with HBsAg adw and genotype C (HBsAg/adr) are gen
GenBank database. These consensus sequences represent the most p
three independent clones from patient T4. Other samples are named
uppercase letters. Deletions are shown by the letter “x”. Most deletions
with an asterisk, sequence identity was found among the same subtyT/N117, T32, N79, N85, and T/N109. In accordance withprevious reports, most of the deletions end their C-
terminus at residue 141 of the preS2 region (Takahashi et
al., 1998). Amino acid 120 (methionine) is the initiation
codon for the M protein and was also frequently deleted
or mutated in 4 of 10 patients (T4, N85, T/N109, and
T/N117). Taken together with previous literature (Fan et
al., 2001; Takahashi et al., 1998), there are two major
types of HBV preS2 variants found in patients with end-
stage liver diseases: one produces truncated M and L
proteins due to a preS2 internal deletion and the other
produces a truncated L protein, but does not produce
region (amino acids 120 to 174) between HBV consensus sequences
e tissue samples containing replicative HBV DNA intermediates, as
NA sequencing analysis. The consensus sequences of HBV genotype
based on all the reported envelope amino acid sequences from the
t sequences in Southeast Asia. Samples T4.2, T4.4, and T4.6 represent
imilar manner. The bona fide mutations are represented in boldface
d within the boxed region. Z represents a stop codon. At the positions
sequence difference was found between different subtypes.preS2
Only th
and D
erated
revalen
in a s
occurreany M protein due to AUG ablation.
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and virion secretion competent
The type of preS2 variant with an ablated AUG initia-
tion codon has been shown to be competent for replica-
tion and infection (Fernholz et al., 1993). On the other
hand, preS2 internal deletions, which spare the AUG
initiation codon, have not thus far been characterized.
Due to the compact organization of the HBV genome, the
preS2 internal deletion overlaps completely with the viral
polymerase gene (Ganem, 1996) and partially with the
promoter region for the transcription of M/S envelope
mRNA (Schaller and Fischer, 1991). PreS2 internal dele-
tions can therefore generate three truncated proteins:
polymerase and the L and M envelope proteins. It is
conceivable that such deletions may have multiple ef-
fects on HBV. We thus examined the effect of the preS2
internal deletion on HBV RNA transcription, DNA repli-
cation, and virion secretion.
We transiently transfected tandem dimer replicons pD32
and pD79 (Fig. 3A) into a human hepatoma cell line, Huh7,
and found no difference in the steady-state level of M/S
envelope mRNAs between WT HBV and preS2 deletion
variants by Northern blot analysis (data not shown). In
addition, to compare the DNA replication and virion secre-
tion between wild-type virus and preS2 deletion variants,
we also analyzed nucleocapsid-associated HBV DNAs by
Southern blot analysis. As shown in Figs. 3C and 3D, both
intracellular viral replication and the profile of virion secre-
tion appeared to be similar in wild-type virus and preS2
deletion variants. Therefore, the truncated HBV polymerase,
caused by preS2 deletion, did not affect viral replication. In
addition, the deleted L and M envelope proteins did not
affect virion secretion.
PreS2 internal deletion variants accumulate more
intracellular envelope proteins and secrete less large
and small envelope proteins
Although we did not find any differences in virion secre-
tion between wild-type virus and preS2 internal deletion
variants, we observed reproducibly a reduced amount of
secreted small envelope HBsAg from HBV preS2 deletion
variants compared to wild-type virus using an enzyme im-
munoassay (Auszyme Monoclonal, Abbott Laboratories).
While the difference in secretion of HBsAg was approxi-
mately twofold, the secretion of another HBV antigen,
HBeAg, was not affected for both pD79 and pD32 [HBe
(rDNA) EIA, Abbott Laboratories] (Fig. 4A). Since the EIA
detects all three HBV envelope proteins (L, M, and S), to
gain a better resolution, we performed Western blot analy-
sis using specific antibodies to identify each individual
envelope protein. Monoclonal antibodies MA18/7 and
Q19/10 are specific for the preS1 and preS2 regions, re-
spectively, while H166 is S-specific and will detect all three
envelope proteins (Materials and Methods). As shown in
Fig. 4B, both preS2 internal deletion variants secreted a
significantly decreased amount of the L envelope protein aswell as a slightly decreased amount of S envelope protein
(lanes 2 and 3 vs lane 4; lanes 10 and 11 vs lane 12) and
accumulated higher intracellular levels of all three envelope
proteins (Fig. 4C, lanes 2 and 3 vs lane 4; lanes 6 and 7 vs
lane 8; lanes 10 and 11 vs lane 12). Most surprisingly, the
secreted mutant M proteins with a preS2 internal deletion
exhibited a more heterogeneous and higher than expected
molecular weight in transiently transfected human hepa-
toma cell line Huh7 (Fig. 4B, lanes 6 and 7 vs lane 8) as well
as in stably transfected rat hepatoma cell line 7777 (Fig.
4D). As an internal control, the amount of nucleocapsid
protein in cells or culture supernatants was measured and
found to be similar in wild-type HBV and deletion variants
(data not shown).
Intracellular retention of HBV envelope proteins in
preS2 variant-transfected cells
To confirm the results of Western blot analysis of these
envelope proteins, we also performed immunofluores-
cence analysis of cells transfected with wild-type HBV or
preS2 variants (Fig. 4E). Consistent with Western blot
analysis (Fig. 4C), the staining signals obtained with
anti-preS1 (MA18/7) and anti-preS2 (Q19/10) were stron-
ger in cells transfected with preS2 internal deletion vari-
ants than with WT HBV. Furthermore, a granular staining
at the perinuclear region suggests that these proteins
were somehow more concentrated with the ER–Golgi
intermediate compartments (Melegari et al., 1997; Xu and
Yen, 1996) (Fig. 4E). In contrast, the wild-type L and M
proteins were distributed more evenly and diffusely
throughout the cytoplasm. In a control experiment, the
immunofluorescence patterns of HBsAg (polyclonal anti-
HBs) and HBcAg (polyclonal anti-HBc) in preS2 deletion
variant-transfected cells were more or less similar to
those of wild-type HBV-transfected cells. In summary,
HBV preS2 deletion has a positive effect on the intracel-
lular accumulation of all three envelope proteins as well
as a modest negative effect on the release of subviral
particles (Fig. 4).
HBV preS2 deletion variants are neutralizing antibody
escape variants
As mentioned earlier, the preS2 region is highly immu-
nogenic and contains several overlapping, yet indepen-
dent, B and T cell epitopes (Meisel et al., 1994; Milich et
al., 1985, 1986; Sobotta et al., 2000). Furthermore, it has
been shown that anti-preS2 antisera can protect chim-
panzees from infection with HBV (Emini et al., 1989; Ito et
al., 1986; Neurath et al., 1986a). Interestingly, the general
vicinity of this immunodominant region also contains the
most frequent deletions among HBV preS2 variants ac-
cording to our results and those of others (Fig. 2; Fan et
al., 2001; Takahashi et al., 1998; Yamamoto et al., 1994).
The close proximity or overlap between naturally occur-
ring preS2 deletions and protective epitopes implies, but
does not prove experimentally, that deleting these pro-
48 TAI ET AL.FIG. 3. (A) The schematic presentation of the two different preS2 deletion variants found in two different patients: D79 and D32. While D79 contains
a 15-amino-acid deletion located between residues 127 and 141 in the preS2 region, D32 carries an 11-amino-acid deletion between residues 131
and 141. (B) The comparison of the amino acid sequence of preS2 120–145 from different HBV serotypes (Galibert et al., 1979; Kobayashi and Koike,
1984; Valenzuela et al., 1980). Their corresponding genotypes are also included (Norder et al., 1992). This region accommodates multiple, overlapping,
but independent B cell epitopes. The putative neutralizing antibody (anti-preS2 120–145, ayw) used in Fig. 5 was raised against a peptide
corresponding to this region. Another independent preS2 monoclonal antibody, Q19/10, recognizes N-glycosylated preS2 120–126 (underlined), which
is located outside the deletion region of D79 and D32. (C) HBV preS2 deletion variants (D79 and D32) can replicate as well as wild-type virus (WT)
as indicated by the results of Southern blot analysis. Wild-type, mutant D79, or mutant D32 HBV DNA was transfected into human hepatoma cell line
Huh7. Replicative intermediates of HBV DNA were isolated from intracellular viral capsid 5 days after transfection and analyzed by Southern blot
analysis using a 3.2-kb full-length HBV DNA probe. Both WT and mutants exhibited the characteristic pattern of HBV replication, including the
full-length 4.0-kb relaxed-circular form (RC) and the full-length 1.5-kb single-stranded form (SS) indicated by arrows. (D) Comparison of the virion
secretion profiles between wild-type HBV and preS2 deletion variants by CsCl gradient centrifugation analysis. HBV preS2 deletion variants (D79 and
D32) secreted virions at a level similar to WT HBV, but secreted HBsAg at about twofold reduced level as compared with WT virus. The procedures
for virion secretion assay were as described previously (Yuan et al., 1999). The enveloped viral particles secreted from cells transfected with both wild
type and mutants were found mainly in fractions 10 and 12 at a density of approximately 1.24 g/cm3. Fractions 2 and 4 with a density around 1.37 g/cm3were also positive for HBV DNA as expected from the nonenveloped nucleocapsid particles.
—Cont
49IMMUNE ESCAPE AND HYPERMODIFICATION OF HBV preS2 VARIANTtective epitopes is the strategy taken by preS2 deletion
variants to escape from host immune surveillance and
help prolong viral persistence.
To test this immunoevasion hypothesis experimentally,
we used a putative neutralizing antiserum of rabbit poly-
clonal origin [anti-preS2 120–145 (ayw)] in Western blot
and immunofluorescence analyses (Fig. 5). Previously, a
similar antiserum raised against HBV preS2 120–145
peptide of serotype adw2 (Fig. 3B) has been shown to be
virus-neutralizing in chimpanzees challenged with infec-
tious HBV (Neurath et al., 1986a). Since D32 and D79 are
of adr origin, to see whether the neutralizing antibody
raised against preS2 120–145 (ayw) can recognize the
preS2 of adr origin from D32 and D79, we performed
Western blot analysis, as shown in the lower panel of Fig.
5A. The results confirmed the prediction from the se-
quence similarity in Fig. 3B that the neutralizing antibody
can indeed cross-react with preS2 regions of different
serotype origins. The size heterogeneity of the wild-type
M proteins of lanes 2–5 in Fig. 5A, lower panel, is prob-
ably in part caused by O-glycosylation (see Discussion).
As shown in the upper panels of Figs. 5A, 5B, and 5C,
our experiments demonstrated that both extracellular
and intracellular M envelope proteins with preS2 internal
deletion (D32 and D79), produced from either the sub-
genomic expression vector or the full-length replicon
systems, cannot be recognized by this putative neutral-
izing antibody. This negative result cannot be attributed
to a low level of production of mutant proteins since they
FIG. 3were easily detectable by another anti-preS2 monoclonalantibody, Q19/10, which recognizes an epitope outside
the deletion region (Fig. 5A, lanes 2, 4, and 6 of the
middle panel; Figs. 5B and 5C, middle panels). This
epitope consists of a sugar and a heptapeptide of preS2
120–126 (Fig. 3B). Because recognition of this epitope by
Q19/10 is sugar-dependent, sugar removal by PNGase F
treatment resulted in a significant decrease or complete
absence of binding by Q19/10 (Fig. 5A, lanes 3, 5, and 7
of the middle panel).
The lack of recognition of mutant M proteins by the
neutralizing antibody (anti-preS2 120–145) was probably
not due to the masking of the preS2 peptide epitope by
any hyper-N-glycosylation around preS2 120–126, as was
reported previously in other viral systems (Alexander and
Elder, 1984; Skehel et al., 1984). In fact, after de-N-glyco-
sylation by PNGase F digestion, the preS2-deleted M
proteins remained unrecognized by this putative neutral-
izing antibody (Fig. 5A, lanes 3 and 5 of the upper panel).
Taken together, our results suggest that HBV preS2 in-
ternal deletion variants can escape in vivo from recog-
nition by the putative neutralizing antibody.
DISCUSSION
Frequent deletions within HBV preS1 and preS2
regions are found at a later stage of chronic HBV
infection
Both frequent and infrequent mutations at the preS2
region have been found in HBV envelope proteins from
inuedserum samples previously (Kidd-Ljunggren et al., 1995;
50 TAI ET AL.FIG. 4. Alterations of the intracellular accumulation and the secreted level of HBV L, M, S, envelope proteins in preS2 variant-transfected culture.
(A) HBV preS2 deletion variants (D79 and D32) secreted approximately 1.5- to 2-fold reduced levels of envelope proteins, as measured by ELISA in
comparison to WT virus (Materials and Methods). This modest but significant effect is specific since the levels of secreted e antigen (HBeAg) in
culture medium remain comparable to those from wild-type HBV transfected cells. The conditioned medium was collected 5 days after transfection.
Two hundred microliters of medium was used to measure HBsAg and HBeAg, respectively. This measurement was performed where a linear
relationship existed between absorbance and HBsAg concentration. Each bar represents the average of three independent experiments. The asterisk
indicates that the difference in the secreted envelope proteins between HBV preS2 deletion variants and wild-type virus is statistically significant (P ,
0.05). (B) Detection of decreased extracellular level of secreted L and, to a lesser extent, S envelope proteins in preS2 deletion variant-transfected
cells by Western blot analysis (lanes 2 and 3 vs lane 4; lanes 10 and 11 vs lane 12). Surprisingly, the secreted preS2 deletion M proteins exhibited
increased heterogeneity and molecular weight (lanes 6 and 7 vs lane 8). (C) Detection of increased intracellular accumulation of L, M, and, to a lesser
51IMMUNE ESCAPE AND HYPERMODIFICATION OF HBV preS2 VARIANTextent, S envelope proteins in preS2 deletion variant-transfected cells (lanes 2 and 3 vs lane 4; lanes 6 and 7 vs lane 8; lanes 10 and 11 vs lane 12) by Western
blot analysis. The wild-type preS2 protein (lane 8) is too faint to be visible in this particular figure. (B and C) The conditioned medium and cell lysates were
collected 6 days after transfection (Materials and Methods). The arrowhead indicates the glycosylated and nonglycosylated forms of L and S envelope
proteins. The asterisks denote the background of cellular proteins that cross-react nonspecifically with the corresponding antibodies. As illustrated in Fig.
1, gp42 and p39 indicate the glycosylated and nonglycosylated L envelope proteins, respectively. gp36 and gp33 are the singly and doubly glycosylated forms
of the M envelope proteins. gp27 and p24 represent the glycosylated and nonglycosylated S envelope proteins. Mock indicates the negative control cells
without transfection (B and C, lanes 1, 5, and 9). (D) Hypermodification of internally deleted M protein is also found in preS2 deletion variant-producing stable
cell lines which were derived from rat Morris hepatoma 7777 (Materials and Methods; Shih et al., 1989). (E) Immunofluorescence staining of three envelope
proteins and core protein in Huh7 cells transfected with WT HBV DNA and preS2 deletion variants (D32 and D79). The staining was performed 3 days after
transfection. The primary antibodies anti-preS1 (MA18/7) and anti-preS2 (Q19/10) were used in B, C, D, and E. Anti-HBs H166 was used in B and C. Anti-HBs
(AXL683) and a rabbit anti-core polyclonal antibody were used in E (Materials and Methods).
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possible explanations for the discrepancy in the literature is
that the patients used in different reports are at different
clinical stages of hepatitis B. Indeed, in our current se-
quencing results, approximately 50% of the HCC samples
from Taiwan were found to contain preS1 or preS2 dele-
tions (data not shown; Fig. 2). However, we detected no
apparent preS2 deletions in 20 Taiwanese chronic carriers
without cirrhosis and HCC (data not shown). The emer-
gence of preS2 deletion variants at later stages of chronic
progression of hepatitis B was noted independently by Fan
et al. (2001) using both serum and liver samples. The main
difference is that Fan et al. studied the type of mutant with
both an internal deletion and a mutation of the start codon
of the M protein. Consequently, such mutants produced no
M protein (Fernholz et al., 1993; Fan et al., 2001). Here, we
focused our study on the mutant M protein containing an
internal deletion.
PreS2 internal deletions have no effect on RNA
transcription, DNA replication, and virion secretion
These preS internal deletion variants are likely to be
viable because the deletions coincide with a dispens-
able spacer region of HBV polymerase (Radziwill et al.,
1990). Indeed, both preS2 internal deletion variants have
no apparent phenotype in RNA transcription (data not
shown), DNA replication, or virion secretion (Fig. 3). This
result is consistent with the fact that preS2 deletion
variants are so prevalent and predominant in late-stage
chronic carriers.
Similarities and differences in envelope protein
secretion and viral pathogenesis between preS1
internal deletion variants and preS2 internal deletion
variants
It has been shown previously that overexpression of
the large envelope protein L invariably results in the
intracellular retention of HBsAg (Chisari et al., 1986; Ou
and Rutter, 1987; Persing et al., 1986). Transfection of
hepatoma cells with the preS1-deleted L envelope pro-
FIG. 5. The immune escape nature of preS2 internal deletion varian
a putative anti-preS2 neutralizing antibody in Western blot and immuno
proteins secreted into the medium were harvested 5 days after transfe
vectors (Materials and Methods). Subviral particles in the medium wer
followed by Western blot analysis. The same filter was analyzed usin
shown in the top panel, the deleted M proteins (pECED32 and pECED79
(ayw), either before or after treatment with PNGase F. As a control, thi
of different genotypes, both before and after treatment with PNGase F (b
upshift of mobility, indicating the lack of O-glycosylation in genotype A
in the filter of the top panel was verified using a sugar-dependent pre
PNGase F removed the sugar and abolished the detection signal in la
is probably due to incomplete digestion by PNGase F. (B and C) The imm
transfected with either subgenomic M protein expression vectors (B) or
as described in (A). Anti-HBs (AXL683) antibody was included here as
control in the top panels of B and C reflect nonspecific background sta
by staining with anti-preS2 Q19/10 indicates a very low level of intracellular rtein also results in reduction of envelope protein secre-
tion (Melegari et al., 1997; Xu and Yen, 1996).
The “ground glass-like” hepatocytes have been de-
scribed in transgenic mice overexpressing the wild-type
L envelope protein under a highly potent albumin pro-
moter (Chisari et al., 1989). In addition, ground glass-like
morphology has also been reported in hepatoma cells
transfected with preS1 deletion variants (Xu and Yen,
1996). Taken together, it was proposed that the endo-
plasmic reticulum loaded with an excessive quantity of
HBV envelope proteins could result in the ground glass
morphology and physiological stress (Melegari et al.,
1997; Xu and Yen, 1996). Indeed, similar ER stress has
also been reported in overloaded ER in several other
viral systems (Berridge et al., 1998; Pahl, 1999).
While preS2 internal deletion variants can behave like
preS1 variants by increasing the intracellular retention of
envelope proteins as well as reducing the secretion of
envelope proteins, there are important qualitative and
quantitative differences between preS1 and preS2 inter-
nal deletion variants: (1) Unlike the L and S envelope
proteins, the secretion of the hypermodified M envelope
protein appears to be increased in preS2 deletion vari-
ants (Fig. 4B) and (2) the effect of preS2 internal deletion
on reducing the secretion of the small S envelope protein
(HBsAg) is modest (less than twofold) (Figs. 4A and 4B).
This modest effect is probably caused indirectly by the
moderate increase in the intracellular level of the large
envelope L protein (Fig. 4C). (3) Despite the increased
intracellular accumulation of viral envelope proteins, we
detected no apparent cytotoxicity in cell cultures trans-
fected with preS2 internal deletion variants (data not
shown). It remains to be seen whether the preS2 inter-
nally deleted M or L proteins can give rise to ground
glass-like morphology.
Increased intracellular level of M protein with a preS2
internal deletion
At present, it remains unclear what could be the cause
of the increased intracellular accumulation of the mutant
ggested by the absence of recognition of their deleted M proteins by
cence microscopic analyses. (A) Briefly, HBV preS2 deletion envelope
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its decreased secretion since the extracellular level of
mutant M protein appears to be increased (Fig. 4B). As
described under Materials and Methods, both wild-type
HBV and its derived pD79 and pD32 mutants have the
same control elements for RNA transcription and the
same context for translational initiation. We therefore
speculate that the cause could be related to translational
elongation or posttranslational events. For example, it
could be in part due to the altered trafficking route of
mutant M proteins (Tai and Shih, unpublished results).
Experiments measuring the half-life of the internally de-
leted M protein could be informative in this respect.
The biochemistry and cell biology of hypermodification
The hypermodification phenomenon of the secreted
preS2-deleted M proteins is surprising since the deleted
M proteins have an apparent molecular weight higher
than the nondeleted wild-type M proteins (Fig. 4B, lanes
6 and 7; Fig. 4D; Fig. 5A, lanes 2 and 4 of the middle
panel). This phenomenon is not an idiosyncracy of any
particular preS2 deletion variant since two different de-
letions found in two patients displayed a similar hyper-
modification phenotype. Because hypermodification is a
phenomenon sensitive to drug treatment blocking the
protein trafficking from the ER to the Golgi (Tai and Shih,
unpublished results), it is unlikely that this phenomenon
is caused by trivial factors, such as altered protein elec-
trophoretic mobility on SDS–PAGE due to altered hydro-
phobicity of the mutant M protein. Preliminary study of
the biochemical nature of hypermodification has ex-
cluded the possibility of polylactosaminoglycans (Tai and
Shih, unpublished results), as was observed in influenza
C virus (Pekosz and Lamb, 1997). The apparently higher
level of expression of hypermodified M protein in preS2
variants is not due to the preferential detection of hyper-
modified M protein by anti-preS2 monoclonal antibody
Q19/10, since we can detect the same results using an
anti-S monoclonal antibody H166 (data not shown). The
possibility that aberrant O-glycosylation could contribute
to the hypermodification phenomenon remains under
active investigation (see further discussion below).
As discussed earlier, it remains unclear what could be
the mechanism of the increased intracellular accumula-
tion of the preS2 deletion protein. In fact, it is equally
unclear whether the increased intracellular accumula-
tion of the preS2 deletion M protein is causal to, or
independent of, the hypermodification of secreted preS2
deletion M protein. While the biological significance of
this aberrant modification remains to be resolved, these
mutant preS2 proteins can serve as a model for studying
the cell biology of the HBV–hepatocyte system.
Genotypes and O-glycosylation
During our study on the nature of the hypermodifica-
tion of variant M proteins, we noted that the wild-type Mprotein can display size heterogeneity probably caused
in part by O-glycosylation near the carboxyl-terminus of
the preS2 region (Fig. 5A, lower panel; Werr and Prange,
1998; Schmitt et al., 1999). It is known that O-glycosyla-
tion occurs in the M- but not the L-protein of HBV geno-
type D (Schmitt et al., 1999) and of woodchuck hepadna-
virus (WHV) (Tolle et al., 1998). Potential O-glycosylation
motifs are also present in genotypes B, C, E, and F of
HBV and in the hepadnaviruses of ground squirrel and
woolly monkey, but not in HBV genotype A.
Although our results in Fig. 5A, lower panel, showed
no M protein size heterogeneity in genotype A (adw2),
suggesting no O-glycosylation for genotype A-specific
preS2 in the tissue culture system, it remains to be
proven if the same can be found in patients. In plasma-
derived M protein, only one threonine residue is linked
with a nested set of the mono-, di-, and trisaccharide
sequence GalNac-Gal-Neu5Ac (Schmitt et al., 1999),
causing a moderate heterogeneity and slight shift of the
apparent molecular weight by 1–2 kDa. In the COS7-cell-
culture-derived M protein of HBV genotype D, a much
stronger O-glycosylation and size heterogeneity were
observed (Werr and Prange, 1998) and the same was
found in plasma-derived M protein from WHV (Tolle et al.,
1998). O-glycosylation occurs in the Golgi apparatus. Our
findings suggest that the hypermodification of the inter-
nally deleted M protein may be related to enhanced
O-glycosylation. The preS2 internal deletion itself over-
laps with the binding site for polymerized human serum
albumin (Sobotta et al., 2000). It is currently open for
speculation how deletion of this site may lead to the
observed consequences for intracellular retention, hy-
permodification, and secretion.
Immunoevasion and emergence of HBV preS2
internal deletion variants
We tested experimentally our immune escape hypoth-
esis at a higher degree of resolution by using the neu-
tralizing antibody (anti-preS2 120–145) raised against
HBV serotype ayw. Previously, antisera raised against
the preS2 region of a specific HBV serotype have been
shown to cross-neutralize HBV of a different serotype
(Emini et al., 1989; Itoh et al., 1986; Neurath et al., 1986a,
1987). Indeed, the amino acid sequences of preS2 120–
145 from different serotypes are very similar (Fig. 3B) and
anti-preS2 antibody (120–145, ayw) can actually recog-
nize different HBV serotypes in Western blot analysis
(Fig. 5A, lower panel). In summary, the fact that the preS2
deletion proteins were not recognized in vitro by the
putative neutralizing antibodies [anti-preS2 120–145
(ayw)] in Western blot and immunofluorescence analyses
(Fig. 5) provides a more direct support to the notion that
HBV preS2 deletion variants are immune escape variants
in vivo. At present, we also entertain the hypothesis that
hypermodification of the M protein can mask some cru-
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escape.
Such a selective advantage of immunoevasion proba-
bly contributes to the emergence of preS2 internal dele-
tion variants in late-stage chronic carriers. Indeed, in
three of three PCR subclones from each of samples D32
and D79, we found only deletion variants, but no wild
type, suggesting a likely predominance of preS2 deletion
variant over wild-type HBV in patients D32 and D79 (Fig.
2). In this regard, it will be interesting to ask if hyper-
modified M protein can be detected in patients in the
future. On the other hand, the preS2 region and M protein
must also have some important unknown functions in
vivo which allow the conservation of the preS2 region
and the maintenance of M envelope protein throughout
evolution.
MATERIALS AND METHODS
DNA transfection of the human hepatoma Huh7 cell
line was carried out by the calcium phosphate protocol
(Roychoudhury et al., 1991). Preparation of HBV viral DNA
and gradient centrifugation analysis of virion secretions
were as detailed elsewhere (Yuan et al., 1999). ELISAs
for HBsAg and HBeAg were performed according to the
vendor’s protocol (Abbott Co.).
Chronic hepatitis B patients with or without cirrhosis
and HCC
Primary hepatoma samples of Taiwanese origin were
obtained from National Taiwan University Hospital and
Chang-Gung Memorial Hospital at Taipei, Taiwan (see
Table 1 in Hosono et al., 1995; Table 1 in Tai et al., 1997).
Both tumor (T) and their cognate nontumor liver samples
(N) were included in this study. Although most hepatoma
samples contain only 0–7 copies of integrated HBV
DNAs (Shih et al., 1996), the hepatoma and nontumorous
liver samples used here are known to contain abundant
unintegrated replicative HBV DNA prescreened by
Southern blot analysis (Hosono et al., 1995; Tai et al.,
1997).
Serum samples were collected from a total of 20 dif-
ferent HBsAg-positive chronic carriers with no detect-
able markers for hepatitus C virus or hepatitis D virus, at
Taipei Medical University Hospital, Taipei, Taiwan. These
patients had no clinically apparent cirrhosis or HCC. This
cohort included 4 females and 16 males. Their ages
ranged from 16 to 59. Nine of these 20 patients were
HBeAg positive and only 5 patients had an ALT value
near or over 100 IU/L. More detailed information on this
cohort, including liver functional tests, abdominal sonog-
raphy, and liver sonography, will be published elsewhere.
PCR amplification, cloning, and DNA sequencing
Preparation of HBV DNA from liver or serum samples
was as described elsewhere (Hosono et al., 1995; Yuanet al., 1998). As mentioned above, only the liver samples
containing detectable replicative HBV DNA intermedi-
ates by Southern blot analysis were used here for PCR
subcloning and DNA sequencing. The PCR product
should therefore reflect the majority of the replicative
forms of HBV DNA. The detailed PCR procedures, includ-
ing oligonucleotide primer sequences for amplification of
preS1, preS2, and S regions, have been described pre-
viously (Tai et al., 1997). Oligonucleotide primers used in
sequencing are as follows: primer nt 2725–2745, 59-AGT
TAA TCA TTA CTT C(C/A)A AAC-39; primer nt 2973–2992,
59-AAT CCA GAT TGG GAC TTC AA-39; primer nt 58–77,
59-CCT GCT GGT GGC TCC AGT TC-39; primer nt 2992–
2973, 59-TTG AAG TCC CAA TCT GGA TT-39; primer nt
3160–3144, 59-CCT GAC TGC CGA TTG GT-39; primer nt
190–170, 59-GGG GTC CTA GGA ATC CTG ATG-39.
Plasmids pD32 and pD79 are tandem dimer replicons
of HBV preS2 internal deletion variants
A wild-type HBV tandem dimer replicon, pSV2Aneo-
HBV2X (serotype ayw), has been reported previously
(Yuan et al., 1999). To construct pD32 and pD79, a DNA
fragment from nt 3213 to 990 encoding HBV preS2 and
HBsAg was PCR amplified from total DNA of liver sam-
ples T32 and N79 (Hosono et al., 1995), respectively. Both
T32 and N79 carried actively replicating HBV variants
with an internal deletion in their preS2 region. PreS2
internal deletions identical to our D32 have been found
by Kohno et al. (1996) using serum samples from a “case
4” chronic carrier. PreS2 internal deletions identical to
our D79 have been found by Kohno et al. (1996) using
serum samples from a “case 2” chronic carrier as well as
by Takahashi et al. (1998) using serum samples from
their chronic carrier No. 16. The sense primer used in
PCR amplification was derived from nt 3213 to 12 (59-ATG
CAG TGG AAT TCC ACA ACA-39). This oligonucleotide
starts with the ATG initiation codon of preS2 ORF and the
EcoRI site (underlined) is at the fourth and fifth codons of
the middle envelope protein. Consequently, the parental
wild-type HBV and its derived mutants pD32 and pD79
have identical transcriptional regulatory elements and
translational initiation context of their M envelope pro-
teins. The antisense primer was from nt 988 to 972
(59-ACT TTC CAA TCA ATA GG-39). The PCR-amplified
product of 0.8 kb was gel-purified after digestion by
EcoRI and AccI. The DNA fragments from T32 and N79
were then used to replace the wild-type monomeric HBV
counterpart in pSV2ANeo-HBV1X before tandem dimer-
ization at the EcoRI site.
Establishment of stable rat Morris hepatoma cell
lines producing mutant M envelope proteins and
active HBV DNA replication
The procedures are as described in Shih et al. (1989).
Tandem dimer replicons, pD32 and pD79, were used as
donor DNAs in stable transfections.
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type (pECEM, adr) and preS2 internal deletion
mutants (pECED79 and pECED32)
The HBV preS2 envelope protein expression vector
(P30) of serotype adw2 was kindly provided by Dr. J. H.
Ou (Ou and Rutter, 1987). P30 was used as a backbone
to construct pECEM, pECED79, and pECED32. Because
HBV sequences from samples T32 and N79 are most
closely related to that of the adr serotype (Fig. 2; Tai et al.,
1997), the DNA fragments containing the preS2/S gene
from nt 3213 to 1840 were amplified by PCR using as
templates the total DNA isolated from T32, N79, and the
plasmid DNA of wild-type HBV of adr serotype origin as
a control (Kobayashi and Koike, 1984). The sense primer
used in PCR amplification was derived from nt 3213 to 12
(59-ATG CAG TGG AAT TCC ACA ACA-39) and the anti-
sense primer was from nt 1840 to 1811 (59-TAGC GAA
TTC TTA GGC AGA GGT GAA AAA GTT GCA TGG TGC-
39). Both primers contained an EcoRI cleavage site (un-
derlined). The standard PCR condition was followed by
annealing at 55°C (Tai et al., 1997). The 1.8-kb EcoRI HBV
fragment containing the preS2/S sequence from either
wild-type adr or preS2 internal deletion mutants was
used to replace the adw2 counterpart in P30. All con-
structs were confirmed by restriction enzyme digestion
and DNA sequencing.
PNGase F treatment
The M protein expression vector-transfected Huh7
cells (3 3 106 cells/10-cm dish) or the concentrated
extracellular subviral particles were denatured by heat-
ing in 100 ml of denaturing buffer (0.5% SDS, 1% 2-mer-
captoethanol) at 100°C for 10 min. The denatured sample
was then incubated with 50 mM sodium phosphate, pH
7.5, 1% NP-40, and 100 units of PNGase F (New England
BioLabs) at 37°C for at least 5 h. After incubation, the
reaction mixture was mixed with an equal volume of 23
protein loading buffer and heated at 100°C for 5 min
before SDS–PAGE and Western blot analysis.
Western blot analysis
Cells from one 10-cm-diameter dish were lysed at 3
days posttransfection with 300 ml of 23 protein loading
buffer. Cell culture medium derived from transfected
cells was collected 5 days posttransfection and centri-
fuged at 2000 rpm (IEC Centra-8) for 30 min to clear
cellular debris. The clarified medium was then layered
on a 20% sucrose cushion and ultracentrifuged at 26,000
rpm in a Beckman SW28 rotor at 4°C for 16 h. The pellet
was resuspended in 150 ml of 23 protein loading buffer.
The intracellular lysates or extracellular pellets were
subjected to 12.5% SDS–PAGE, which was followed by
transfer to nitrocellulose (Schleicher and Schuell). The
membrane was incubated with the primary antibody and
then the secondary antibody conjugated to either horse-radish peroxidase or alkaline phosphatase. The proteins
were detected either using the ECL chemiluminescence
kit (Amersham) or with a Sigma Fast BCIP/NBT (5-bromo-
4-chloro-3-indolyl phosphate/nitro blue tetrazolium) sub-
strate according to the manufacturers’ protocols.
Immunofluorescence microscopy
Transfected cells were grown on coverslips, washed
once in PBS, and fixed with cold methanol:acetone mix-
ture (1:1, v/v). After incubation with blocking solution at
room temperature for 30 min, the primary antibody was
applied and incubated at room temperature for 1 h. After
removal of the primary antibody with several washes of
PBS (0.2% Tween 20), the cells were incubated with the
fluorochrome (fluorescein isothiocyanate or rhodamine)-
conjugated secondary antibody according to the manu-
facturers’ instructions (Sigma and Santa Cruz Biotechnol-
ogy, Inc.). The stained cells were visualized under an
immunofluorescence microscope (Nikon).
Polyclonal and monoclonal antibodies
Most of the antibodies were used at a final concen-
tration of 2–5 mg/ml and were 100- to 500-fold dilutions
from original stocks. Anti-preS1 (MA18/7): a monoclonal
antibody which reacts with all HBsAg serotypes and
binds selectively to gp42 and p39 of HBV L envelope
proteins (Heermann et al., 1984). Anti-preS2 (Q19/10): a
monoclonal antibody which reacts with all HBV geno-
types and binds specifically to gp36 and gp33 of N-
glycosylated M proteins (Heermann et al., 1987). It de-
tects the amino-terminal glycopeptide region of the M
protein. Anti-preS2 aa 120–145, ayw: Rabbit polyclonal
antibodies were prepared as described previously
(Neurath et al., 1986a). Anti-HBs: (1) H166: This monoclo-
nal anti-HBs antibody was a generous gift from Dr. D. L.
Peterson (Peterson et al., 1984). It reacts with all HBsAg
serotypes and binds to all three envelope proteins (L, M,
and S). Anti-HBs: (2) AXL683: a goat anti-HBsAg specific
for serotypes ad/ay from Accurate Chemical and Scien-
tific Corp. (Westbury, NY). Anti-core: a rabbit polyclonal
antiserum against HBV core antigen (HBcAg) was ob-
tained from Dr. R. Lanford (Lanford et al., 1987).
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